Market News How it works Learn FAQ
| RCT 0.132 73.46% | NU 12.36 -18.47% | EWZ 33.885 -20.44% | TGL 0.254 14.67% | SRTM 0.326 -24.24% | BBD 2.855 -29.85% | ITUB 7.6 -21.41% | AZTR 1.615 125.87% | SHFS 0.103 -22.21% | XP 15.575 -48.78% | GCDT 0.1361 -22.71% | CLRO 4.79 47.38% | SOXL 91.64 9.67% | SPCX 149.92 1.65% | NWGL 0.0829 1.10% | PBR 21.94 -16.13% | NVD 3.99 -4.77% | SGRY 23.0703 46.48% | TSLL 10.9599 12.29% | VALE 11.99 -3.31% | RBNE 0.1701 -10.47% | CRWV 57.4626 5.95% | INTC 90.785 4.40% | NVDA 216.2072 2.49% | SOXS 47.41 -9.63% | BITO 10.77 -0.55% | ABEV 2.8 -15.15% | IREN 26.5486 6.60% | JBLU 2.295 -12.57% | NOK 8.625 5.96% | XTND 2.2 24.29% | SPRC 1.5001 37.62% | GPUS 0.1782 5.51% | TQQQ 69.14 4.30% | SBS 4.765 -25.55% | INTR 4.6286 -35.62% | TSLG 5.48 12.53% | RWM 14.435 -0.79% | TSLA 395.443 6.24% | SPDN 8.475 -0.76% | SQQQ 37.975 -4.30% | AAL 12.2055 0.79% | SID 0.9269 -21.45% | GGB 4.765 -6.57% | PBR-A 19.3388 -17.81% | RENT 2.9015 26.15% | LUCD 0.5155 25.43% | CIFR 8.1475 2.61% | KORU 10.9537 3.53% | WULF 12.08 6.71%
MNMediciNova, Inc. logo

MediciNova, Inc. (MNOV)

NASDAQ Global Market · Currency in USD
$1.47 ▲ +0.08 (+5.76%)
As of Oct 26, 11:54 AM ET. Market open.

Summary

Previous Close
$1.39
Open
$1.44
Day's Range
$1.44 – $1.47
52 Week Range
$1.17 – $3.90
Volume
28,800
Avg. Volume
251,042
Market Cap
$72.36M
Beta (5Y Monthly)
0.61
PE Ratio (TTM)
--
EPS (TTM)
-$0.22
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$6.00

Profile: MediciNova, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
6
CEO
Yuichi Iwaki

MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.06 · Revenue est. $50.00K
DateEst.Actual
Aug 13, 2026-$0.06-$0.05Beat
May 15, 2026-$0.06-$0.05Beat
Feb 20, 2026-$0.10-$0.06Beat
Nov 13, 2025-$0.08-$0.06Beat
Aug 14, 2025-$0.07-$0.07Beat
May 14, 2025-$0.14-$0.06Beat

Analyst view

Consensus price target
$6.00 ▲ +308.2%
Range $6.00 – $6.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on MNOV and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.